Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia. (28th July 2014)

• Record Type: Journal Article
• Authors: van Dijk, P.R.; Logtenberg, S.J.J.; Gans, R.O.B.; Bilo, H.J.G.; Kleefstra, N.
• Is Part Of: Clinical endocrinology. Volume 81:Number 4(2014:Oct.)
• Page Start: 488
• Page End: 497
• Publication Date: 2014-07-28
• Subjects: Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.12546
• Languages: English
• ISSNs: 0300-0664

Abstract

<abstract abstract-type="main" id="cen12546-abs-0001"> <title>Summary</title> <p>Continuous intraperitoneal insulin infusion (CIPII) is a treatment option for patients with type 1 diabetes mellitus who fail to reach adequate glycaemic control despite intensive subcutaneous (SC) insulin therapy. CIPII has clear advantages over SC insulin administration in terms of pharmacokinetic and pharmacodynamic properties and has been shown to improve glycaemic regulation. Due to the delivery of insulin predominantly in the portal vein, as opposed to systemically, CIPII offers a unique research model to investigate the effects of insulin on endocrine and metabolic parameters <italic>in vivo</italic>. The aim of the present article is to provide an overview of the literature with respect to the effects of CIPII on glucose management, quality of life, complications and costs, with additional focus on metabolic and endocrine aspects. Finally, future use and research objectives are discussed.</p> </abstract>